A Snapshot of Different Types of Under Research Vaccines Against COVID-19: A Review
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-7 (e7)
https://doi.org/10.22037/amls.v6.32379
Abstract
SARS-CoV-2 as an emerging coronavirus, which first emerged in late 2019 in China causes a respiratory disease called “Coronavirus Disease 2019 (COVID-19)’’. SARS-CoV-2 has since infected more than 26 million people worldwide and caused more than 864000 deaths as of September 04, 2020. The SARS-CoV-2 spike (S) protein consists of two subunits: S1 and S2, which plays a role in binding to cellular receptors and mediating the fusion process between the membranes of the virus and host cells. The S protein has an important role to induce neutralizing-antibody, as well as protective immunity, during SARS-CoV-2 infection. In this review, we focused on different types of the vaccine against COVID-19.
*Corresponding Author: Maryam Fazeli; Email: m.fazeli@umsha.ac.ir
Please cite this article as: Zandi M, Rashid S, Nasimzade S, Pourhossein B, Fazeli M. A Snapshot of Different Types of Under Research Vaccines Against COVID-19: A Review. Arch Med Lab Sci. 2020;6:1-7 (e7). https://doi.org/10.22037/amls.v6.32379
- SARS- 2
- Vaccine
- Novel Coronavirus
- Coronavirus Disease 2019
- SARS-CoV-2
- Covid-19
How to Cite
References
Kasmi Y, Khataby K, Souiri A, Ennaji MM. Coronaviridae: 100,000 Years of Emergence and Reemergence. Emerging and Reemerging Viral Pathogens: Elsevier; 2020. p. 127-49.
Kim JM, Chung YS, Jo HJ, Lee NJ, Kim MS, Woo SH, Park S, Kim JW, Kim HM, Han MG. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong public health and research perspectives. 2020; 11(1):3-7.
Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. Journal of medical virology. 2020; 92(6):595-601.
Navand AH, Soltani S, Moghadami M, Hosseini P, Nasimzadeh S, Zandi M. Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2). Journal of Acute Disease. 2020; 9(6):244.
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24:91-98.
Tison GH, Avram R, Kuhar P, Abreau S, Marcus GM, Pletcher MJ, Olgin JE. Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study. Ann Intern Med. 2020; 173(9):767-70.
Lie SA, Wong SW, Wong LT, Wong TGL, Chong SY. Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic. Can J Anaesth. 2020; 67(7):885-92.
Wang L, Wang Y, Ye D, Liu Q. Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948]. Int J Antimicrob Agents. 2020; 56(3):106137.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 13;7(1):11.
Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, Peng L. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. Int J Infect Dis. 2020; 93:297-9.
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020; 26;12(3):e7423.
Poortahmasebi V, Zandi M, Soltani S, Jazayeri SM. Clinical performance of RT-PCR and chest CT scan for COVID-19 diagnosis; a systematic review. Advanced Journal of Emergency Medicine. 2020 May 29;4(2s):e57.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine. 2020 May 5;172(9):577-82.
de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, Andrews N, Byford R, Dabrera G, Elliot A, Ellis J. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. The Lancet Infectious Diseases. 2020 ; 20(9): 1034-1042.
Ludvigsson JF. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica. 2020 Jun;109(6):1088-95.
Nerli S, Sgourakis NG. Structure-based modeling of SARS-CoV-2 peptide/HLA-A02 antigens. bioRxiv [preprint]. 2020 .
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou QJS. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8.
Fani M, Teimoori A, Ghafari S. Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virology. 2020; 15(5): 317-323 .
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine. 2020;46(4):586-90.
Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica. 2020 ; 3:1-9.
White JM, Delos SE, Brecher M, Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Critical reviews in biochemistry and molecular biology. 2008 Jan 1;43(3):189-219.
Carino A, Moraca F, Fiorillo B, Marcanó S, Sepe V, Biagioli M, Finamore C, Bozza S, Francisci D, Distrutti E, Catalanotti B. Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region. Front Chem. 2020 ; 23(8): 572885.
Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, Aziz B. Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein. Journal of Med. Virol. 2020; 92(2): 1-7.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-20.25.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 ; 181(2): 271-280.
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020; 181(4): 894-904.
Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically-sensitive activation loop. Journal of molecular biology. 2020; 432(10): 3309-25.
Mangar P, Pradhan S, Rai S, Lepcha K, Ranjan VK, Rai A. Comparative Analysis Based on the Spike Glycoproteins of SARS-CoV2 Isolated from COVID 19 Patients of Different Countries. Preprints.org; 2020. DOI: 10.20944/preprints202004.0154.v1.2020.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circulation research. 2020;126(10):1456-74.
Korber B, Fischer W, Gnanakaran SG, Yoon H, Theiler J, Abfalterer W, Foley B, Giorgi EE, Bhattacharya T, Parker MD, Partridge DG. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. Cell. 2020 ; 182(4):794-5.
Bhattacharyya C, Das C, Ghosh A, Singh AK, Mukherjee S, Majumder PP, Basu A, Biswas NK. Global spread of SARS-CoV-2 subtype with spike protein mutation D614G is shaped by human genomic variations that regulate expression of TMPRSS2 and MX1 genes. bioRxiv. 2020 Jan 1.
Sanami S, Zandi M, Pourhossein B, Mobini GR, Safaei M, Abed A, Arvejeh PM, Chermahini FA, Alizadeh M. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach. International journal of biological macromolecules. 2020 Dec 1;164:871-83.
Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette AJCh, et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell host & microbe. 2020; 27(4): 671-680.
Mao HH, Chao SJCAoPB. Advances in Vaccines. Adv Biochem Eng Biotechnol.2020; 171:155-88.
Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin MJS. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020; 369(6501):330-333.
Lurie N, Saville M, Hatchett R, Halton JJNEJoM. Developing Covid-19 vaccines at pandemic speed. 2020;382(21):1969-73.
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccin Immunother. 2020; 16(6):1232-1238.
World WHOJ. DRAFT landscape of COVID-19 candidate vaccines. 2020.
Pagliusi S, Jarrett S, Hayman B, Kreysa U, Prasad SD, Reers M, et al. Emerging Manufacturers engagements in the COVID-19 vaccine research, development and supply. Vaccine.2020.
Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Current opinion in biotechnology. 2007;18(6):546-56.
Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264-6.
van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020.
Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2. F1000Research. 2020;9: F1000.
Gao Q, Bao L, Mao H, Wang L, Xu K, Li Y, et al. Development of an inactivated vaccine for SARS-CoV-2. Science. 2020; 3;369(6499):77-81.
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Lague J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. BioRxiv. 2020 Jan 1.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020 Oct 20.
Dolzhikova I, Tokarskaya E, Dzharullaeva A, Tukhvatulin A, Shcheblyakov D, Voronina O, et al. Virus-vectored Ebola vaccines. Acta Naturae (англоязычная версия). 2017;9(3 ):4-11.
- Abstract Viewed: 207 times
- PDF Downloaded: 83 times